Technetium-99m labeled Ibuprofen: Development and biological evaluation using sterile inflammation induced animal models
- 36 Downloads
In this study we are presenting the development of technetium-99m (99mTc) labeled ibuprofen for the imaging of aseptic inflammation. 99mTc-Ibuprofen complex was developed by optimizing the radiolabeling conditions such as reaction time, ligand and reducing agent concentration, pH, reaction time and temperature. Following the addition of 600 µg of ibuprofen, 4 µg of stannous chloride as reducing agent and 300 MBq 99mTc radioactivity; the pH of reaction mixture was adjusted to 11 and allowed to react for 15 min at room temperature. Chromatography analysis revealed > 94% 99mTc-ibuprofen complex formation with promising stability in saline and blood serum up to 6 h. Biodistribution study using normal and sterile inflammation induced mice indicated low accumulation of labeled compound in key body organs; however, kidneys (14.76 ± 0.87% ID/g organ) and bladder (31.6 ± 3.0% ID/g organ) showed comparatively higher radioactivity due to main excretory path. Inflamed to normal tissues ratio (T/NT), at 1 h post-injection, showed promising value (4.57 ± 0.56). The SPECT imaging of artificially inflammation induced rabbit model also verified the biodistribution results. In conclusion, radiochemical purity and biological evaluation of 99mTc-ibuprofen complex indicates the agent can be utilized for imaging of deep seated aseptic inflammation.
KeywordsRadiopharmaceuticals Nuclear medicine Infection imaging Ibuprofen 99mTc-Ibuprofen
The study is a part of HEC funded Project No. 5612/Punjab/NRPU/R&D/HEC/2016, thanks to HEC, GCU Faisalabad, and PINSTECH Islamabad for providing resources and platform to conduct this research.
This study was funded by Higher Education Commission (HEC), Islamabad, Pakistan under Grant No. 5612/Punjab/NRPU/R&D/HEC/2016.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The article is in compliance with ethical standards with approval from ethical review committee.
Informed consent was taken from all co-authors before submission of manuscript.
- 1.Martínez-Rodríguez I, Carril J (2013) Update on the use of PET radiopharmaceuticals in inflammatory disease. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 32:378–386Google Scholar
- 2.Kyprianidou P, Tsoukalas C, Chiotellis A, Papagiannopoulou D, Raptopoulou CP, Terzis A, Pelecanou M, Papadopoulos M, Pirmettis I (2011) First example of well-characterized Re and 99 m Tc tricarbonyl complexes of ciprofloxacin and norfloxacin in the development of infection-specific imaging agents. Inorg Chim Acta 370:236–242CrossRefGoogle Scholar
- 5.Fazli A, Salouti M, Ahmadi G, Mirshojaei SF, Mazidi M, Heidari Z (2012) Radiolabeling of ceftriaxone with 99 m Tc as a Targeting radiopharmaceutical for Staphylococcus aureus detection in mouse model. Iran J Med Phys 9:103–110Google Scholar
- 7.Larikka MJ, Ahonen AK, Niemela O, Junila JA, Hamalainen MM, Britton K, Syrjala HP (2002) Comparison of 99mTc ciprofloxacin, 99mTc white blood cell and three-phase bone imaging in the diagnosis of hip prosthesis infections: improved diagnostic accuracy with extended imaging time. Nucl Med Commun 23:655–661CrossRefGoogle Scholar
- 9.Hughes DK (2003) Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67 Ga-citrate. J Nucl Med Technol 31:196–201 (quiz 203–194)Google Scholar
- 14.Sarda L, Crémieux A-C, Lebellec Y, Meulemans A, Lebtahi R, Hayem G, Génin R, Delahaye N, Huten D, Guludec L, D (2003) Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases. J Nucl Med 44:920–926Google Scholar
- 16.Yadav MR, Pawar VP, Marvaniya SM, Halen PK, Giridhar R, Mishra AK (2008) Site specific chemical delivery of NSAIDs to inflamed joints: Synthesis, Biological activity and γ-imaging studies of quaternary ammonium salts of tropinol esters of some NSAIDs or their active metabolites. Bioorganic Med Chem 16:9443–9449CrossRefGoogle Scholar
- 17.Iqbal A, Naqvi SAR (2018) Radiosynthesis and Biodistribution of (99 m)Tc-Metronidazole as an Escherichia coli Infection. Imaging Radiopharm 185:127–139Google Scholar
- 21.Bushra R, Aslam N (2010) An overview of clinical pharmacology of Ibuprofen. Oman Med J 25:155–1661Google Scholar
- 23.Shahnazarian V, Ramai D, Reddy M (2018) A rare case of ibuprofen-induced acute liver injury. Cureus 10:e3225Google Scholar
- 26.Chianelli M, Signore A, Ronga G, Fritzberg A, Mather S (1994) Labeling, purification and biodistribution of 99 m Tc-interleukin-2: a new radiopharmaceutical for in vivo detection of activated lymphocytes. Eur J Nucl Med 21:807Google Scholar